Lixisenatide (revision 21)
Old revision·16:34, 25 Jan 2026·DulaglutideDug
| LixisenatideClinical data | |
|---|---|
| Class | GLP-1 receptor agonist |
| Origin | Exendin-4 derivative |
| Route | Subcutaneous, once daily |
| Outcome trial | ELIXA; neutral |
| Compound infobox · conventions | |
Lixisenatide is a GLP-1 receptor agonist derived from exendin-4, the same scaffold as exenatide, with a modified C-terminus. It is short-acting and given once daily.[1]
Its pharmacological profile emphasises postprandial glycaemic control through pronounced delay of gastric emptying, an effect that does not attenuate as it does with continuously present long-acting agonists.[2]
The ELIXA trial randomised people with type 2 diabetes and a recent acute coronary syndrome and reported no difference in cardiovascular outcomes. That neutral result is one of the principal reasons cardiovascular benefit is not treated as a class property.[1]
Pharmacology
[edit]Like exenatide, lixisenatide carries glycine at position 2 of the exendin scaffold and is therefore not a substrate for DPP-4. Its half-life of about three hours nonetheless requires daily dosing, since renal clearance dominates once proteolysis is removed.[2]
The short exposure profile produces a large gastric-emptying effect at each dose, and it is this rather than a large fasting-glucose effect that drives its glycaemic action. Its effect on glycated haemoglobin is modest by current standards.[1]
Non-attenuating emptying delay is a genuine pharmacological difference from the weekly agents and is the reason short-acting agents retain a niche where postprandial excursions are the problem.[2]
ELIXA and its significance
[edit]ELIXA randomised 6,068 participants with type 2 diabetes within 180 days of an acute coronary syndrome, and reported a hazard ratio of 1.02 for the primary composite — a clearly neutral result establishing non-inferiority without any suggestion of benefit.[1]
Set beside LEADER and SELECT, which were positive, and the exenatide outcome trial, which was neutral, the pattern within the class is mixed. Whether the differences reflect molecule, exposure profile, population or trial size is unresolved.[2]
The practical discipline this supports is to attribute outcome findings to the trial that produced them rather than to the class. See GLP-1 receptor agonist.[1]
Current position
[edit]Lixisenatide has been largely displaced by weekly agents with larger effects and simpler administration, and by fixed combinations with basal insulin in which its postprandial action complements the basal agent.[2]
It is not commonly encountered in research-chemical supply relative to the weekly analogues, which reflects demand rather than any property of the molecule.[3] As a 44-residue exendin derivative it presents the ordinary synthetic-peptide characterisation problem.[4]
Its lasting significance is evidential: it is the clearest single counter-example to a class-wide cardiovascular claim.[1]
See also
References
- ^ a b c d e f Pfeffer MA, Claggett B, Diaz R, et al. "Lixisenatide in patients with type 2 diabetes and acute coronary syndrome." New England Journal of Medicine 373(23):2247–2257 (2015). PMID 26630143.
- ^ a b c d e Drucker DJ. "Mechanisms of action and therapeutic application of glucagon-like peptide-1." Cell Metabolism 27(4):740–756 (2018). PMID 29617641.
- ^ PeptidePedia Wiki community test-report tally, 2024–2026 (self-reported; see Project:Sourcing guidelines).
- ^ United States Pharmacopeia, General Chapter <1503>, Quality Attributes of Synthetic Peptide Drug Substances.